Prof. Mian Xi 习勉
Chief Physician, Professor
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for thoracic and abdominal tumors, with a focus on esophageal cancer and liver cancer.
Dr. Xi holds a doctorate in oncology and serves as Deputy Director of the Guangdong Esophageal Cancer Institute. A core member of the esophageal cancer expert team, Dr. Xi visited M.D. Anderson Cancer Center from 2016 to 2017. Selected for talent programs in 2011 and 2015, Dr. Xi has served as Deputy Director since December 2021.
Professional roles
- Standing Committee Member, Tumor Radiotherapy Professional Committee, China Medical Education Association
- Standing Committee Member, Comprehensive Treatment Professional Committee, Guangdong Liver Disease Society
- Standing Committee Member, Thoracic Tumor Professional Committee, Guangdong Grassroots Medicine Association
- Member, Liver Cancer and Esophageal Cancer Study Groups, Radiation Oncology Branch, Chinese Medical Association
Name order: in Chinese the family name comes first (Xi Mian). Papers usually list the name as Mian Xi or Xi M.
Selected publications
84 papers on PubMed matched by name and affiliation; 34 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Rep Med, 2026 (senior author): Prognostic value of cfDNA methylation in locally advanced esophageal squamous cell cancer treated with neoadjuvant immunochemoradiotherapy. PubMed 42849445
- J Clin Oncol, 2026 (senior author): Reply to: "Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration" and "NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002". PubMed 42555897
- J Clin Oncol, 2026 (senior author): Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). PubMed 41962116
- Eur J Cancer, 2026 (senior author): Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials. PubMed 41833569
- Br J Cancer, 2026 (senior author): Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysis. PubMed 41419640
- J Immunother Cancer, 2026 (senior author): Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trials. PubMed 41526165
- Ann Med, 2025 (senior author): Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trials. PubMed 41123456
- Drug Resist Updat, 2025 (senior author): RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma. PubMed 40911942
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion